Assessment of HAE prophylaxis transition from androgen therapy to berotralstat: A subset analysis of the APeX-S trial

BACKGROUND: Given the recent approval of oral berotralstat in several countries for hereditary angioedema (HAE) prophylaxis, transition from long-term androgens to berotralstat may occur in clinical practice. The open-label, Phase II APeX-S trial provided an opportunity to assess the safety and effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Peter, Jonny G., Desai, Bhavisha, Tomita, Dianne, Collis, Phil, Stobiecki, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2023
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665923/
https://www.ncbi.nlm.nih.gov/pubmed/38020288
http://dx.doi.org/10.1016/j.waojou.2023.100841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665923/
https://www.ncbi.nlm.nih.gov/pubmed/38020288
http://dx.doi.org/10.1016/j.waojou.2023.100841

Ejemplares similares